NO963506D0 - 4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidler - Google Patents
4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidlerInfo
- Publication number
- NO963506D0 NO963506D0 NO963506A NO963506A NO963506D0 NO 963506 D0 NO963506 D0 NO 963506D0 NO 963506 A NO963506 A NO 963506A NO 963506 A NO963506 A NO 963506A NO 963506 D0 NO963506 D0 NO 963506D0
- Authority
- NO
- Norway
- Prior art keywords
- heterocyclyl
- preparation
- cancer agents
- quinazoline derivatives
- substituted quinazoline
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20025994A | 1994-02-23 | 1994-02-23 | |
PCT/IB1995/000061 WO1995023141A1 (en) | 1994-02-23 | 1995-01-27 | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
Publications (2)
Publication Number | Publication Date |
---|---|
NO963506D0 true NO963506D0 (no) | 1996-08-22 |
NO963506L NO963506L (no) | 1996-10-22 |
Family
ID=22740969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO963506A NO963506L (no) | 1994-02-23 | 1996-08-22 | 4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidler |
Country Status (22)
Country | Link |
---|---|
US (1) | US5736534A (no) |
EP (1) | EP0746554A1 (no) |
JP (1) | JP2890267B2 (no) |
KR (1) | KR100225721B1 (no) |
CN (1) | CN1141633A (no) |
AU (1) | AU686843B2 (no) |
BR (1) | BR9506936A (no) |
CA (1) | CA2183655C (no) |
CO (1) | CO4340688A1 (no) |
CZ (1) | CZ288955B6 (no) |
FI (1) | FI963283A (no) |
HU (1) | HUT76291A (no) |
IL (1) | IL112673A0 (no) |
MX (1) | MX9603593A (no) |
NO (1) | NO963506L (no) |
NZ (1) | NZ278135A (no) |
PE (1) | PE4896A1 (no) |
PL (1) | PL315941A1 (no) |
RU (1) | RU2137762C1 (no) |
TW (1) | TW404946B (no) |
WO (1) | WO1995023141A1 (no) |
ZA (1) | ZA951458B (no) |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE37650E1 (en) | 1991-05-10 | 2002-04-09 | Aventis Pharmacetical Products, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
TW321649B (no) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
EP0824525B1 (en) * | 1995-04-27 | 2001-06-13 | AstraZeneca AB | Quinazoline derivatives |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
WO1997027199A1 (en) * | 1996-01-23 | 1997-07-31 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
US5760041A (en) * | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
KR19990082463A (ko) | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
AU2193797A (en) * | 1996-03-01 | 1997-09-16 | Chiron Corporation | Delivery of therapeutic agents to the prostate |
CN1116286C (zh) | 1996-03-05 | 2003-07-30 | 曾尼卡有限公司 | 4-苯胺基喹唑啉衍生物 |
IL126351A0 (en) | 1996-04-12 | 1999-05-09 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
GB9707800D0 (en) * | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
EP0837063A1 (en) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
WO1998023613A1 (en) * | 1996-11-27 | 1998-06-04 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US5929080A (en) * | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
WO1999010349A1 (en) * | 1997-08-22 | 1999-03-04 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
US6323209B1 (en) | 1997-11-06 | 2001-11-27 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
JPH11236333A (ja) * | 1997-12-30 | 1999-08-31 | Pfizer Prod Inc | 抗ガン剤として有用なイミダゾリン−4−オン誘導体 |
US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
BR9914164A (pt) | 1998-09-29 | 2001-06-26 | American Cyanamid Co | Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto |
US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6174903B1 (en) | 1998-12-28 | 2001-01-16 | Pfizer Inc. | Imidazolidin-4-one derivatives useful as anticancer agents |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
KR100838617B1 (ko) | 1999-02-10 | 2008-06-16 | 아스트라제네카 아베 | 혈관형성 억제제로서의 퀴나졸린 유도체 |
EE200100603A (et) * | 1999-05-14 | 2003-02-17 | Imclone Systems Incorporated | Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega |
US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
PT1244647E (pt) | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
EP1274692B1 (en) | 2000-04-07 | 2006-08-02 | AstraZeneca AB | Quinazoline compounds |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
AU9500201A (en) * | 2000-08-09 | 2002-02-18 | Imclone Systems Inc | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
SK2142003A3 (en) | 2000-08-21 | 2003-07-01 | Astrazeneca Ab | Quinazoline derivatives, process for their preparation, pharmaceutical composition comprising same and their use |
EP1326859A1 (en) | 2000-10-13 | 2003-07-16 | AstraZeneca AB | Quinazoline derivatives with anti-tumour activity |
AU2001292137A1 (en) | 2000-10-13 | 2002-04-22 | Astrazeneca Ab | Quinazoline derivatives |
US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
ES2312557T3 (es) | 2001-04-19 | 2009-03-01 | Astrazeneca Ab | Derivados de quinazolina. |
US6995171B2 (en) | 2001-06-21 | 2006-02-07 | Agouron Pharmaceuticals, Inc. | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents |
US20030144308A1 (en) * | 2001-09-24 | 2003-07-31 | Bauer Paul H. | Fructose 1,6-bisphosphatase inhibitors |
CN101607958A (zh) * | 2002-02-01 | 2009-12-23 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物 |
JP2005527511A (ja) | 2002-03-01 | 2005-09-15 | ファイザー インコーポレイテッド | 抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法 |
SE0200979D0 (sv) | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
US20030202973A1 (en) * | 2002-04-29 | 2003-10-30 | Dr. George Pieczenik | Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists |
UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
CA2494061C (en) * | 2002-07-31 | 2011-06-14 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
US7629347B2 (en) * | 2002-10-09 | 2009-12-08 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
EP1622941A2 (en) * | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
MXPA06002296A (es) | 2003-08-29 | 2006-05-22 | Pfizer | Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos. |
MXPA06007242A (es) | 2003-12-23 | 2006-08-18 | Pfizer | Nuevos derivados de quinolina. |
GB0330002D0 (en) | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
EP1735348B1 (en) * | 2004-03-19 | 2012-06-20 | Imclone LLC | Human anti-epidermal growth factor receptor antibody |
UA85706C2 (en) * | 2004-05-06 | 2009-02-25 | Уорнер-Ламберт Компани Ллси | 4-phenylaminoquinazolin-6-yl amides |
WO2005116035A1 (en) | 2004-05-27 | 2005-12-08 | Pfizer Products Inc. | Pyrrolopyrimidine derivatives useful in cancer treatment |
AR050948A1 (es) | 2004-09-24 | 2006-12-06 | Hoffmann La Roche | Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer. |
US7285569B2 (en) | 2004-09-24 | 2007-10-23 | Hoff Hoffmann-La Roche Inc. | Tricycles, their manufacture and use as pharmaceutical agents |
WO2006108489A1 (en) | 2005-04-14 | 2006-10-19 | F. Hoffmann-La Roche Ag | Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents |
US20070093515A1 (en) * | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
JP2009527560A (ja) * | 2006-02-21 | 2009-07-30 | アムゲン インコーポレイティッド | ホスホジエステラーゼ10阻害剤としてのシンノリン誘導体 |
WO2007100880A1 (en) * | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
US20090099175A1 (en) * | 2006-03-01 | 2009-04-16 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
WO2007129745A1 (ja) | 2006-05-09 | 2007-11-15 | Daiichi Sankyo Company, Limited | ヘテロアリールアミド低級カルボン酸誘導体 |
JP5571387B2 (ja) | 2007-01-11 | 2014-08-13 | クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド | 癌の治療のための化合物および方法 |
US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
WO2009079797A1 (en) * | 2007-12-26 | 2009-07-02 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
MX2010013920A (es) * | 2008-06-26 | 2011-02-21 | Amgen Inc | Alcoholes alquinilicos como inhibidores de cinasas. |
CA2730890C (en) | 2008-07-17 | 2018-05-15 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
CA2999435A1 (en) | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
CN102786512A (zh) * | 2012-05-31 | 2012-11-21 | 中国人民解放军军事医学科学院毒物药物研究所 | N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用 |
CN108125961B (zh) * | 2018-01-24 | 2020-05-26 | 浙江工业大学 | 吗啉基乙酰氨基甲氧苯基苯并氮杂*基喹唑啉类化合物在制备治疗白血病药物中的应用 |
CN108250185B (zh) * | 2018-01-24 | 2020-08-21 | 浙江工业大学 | 6-(2-(邻甲苯氨基)乙酰氨基)喹唑啉类化合物及制备和应用 |
CN108295076B (zh) * | 2018-01-24 | 2020-05-22 | 浙江工业大学 | 丙酰氨基二甲氧基苯并[d]氮杂*基喹唑啉类在制备治疗肺癌药物中的应用 |
CN108014116B (zh) * | 2018-01-24 | 2020-08-21 | 浙江工业大学 | 氨基二甲氧基苯并[d]氮杂*基喹唑啉类化合物在制备治疗肺癌药物中的应用 |
CN108129460B (zh) * | 2018-01-24 | 2020-10-09 | 浙江工业大学 | 甲氧苯基苯并[d]氮杂*基喹唑啉类化合物及制备和应用 |
CN108014112B (zh) * | 2018-01-24 | 2020-10-09 | 浙江工业大学 | 邻甲苯氨基乙酰氨基苯并[d]氮杂*基喹唑啉类化合物在制备治疗肺癌药物中的应用 |
CN108084162B (zh) * | 2018-01-24 | 2019-11-29 | 浙江工业大学 | 二甲氧基苯氨基乙酰氨基苯并[d]氮杂*基喹唑啉类化合物及制备和应用 |
CN108125960B (zh) * | 2018-01-24 | 2020-08-21 | 浙江工业大学 | 异丁酰氨基苯并[d]氮杂*基喹唑啉类化合物在制备治疗肺癌药物中的应用 |
CN108014113B (zh) * | 2018-01-24 | 2020-10-09 | 浙江工业大学 | 丁酰氨基二甲氧基苯并[d]氮杂*基喹唑啉类化合物在制备治疗宫颈癌药物中的应用 |
CN108033949B (zh) * | 2018-01-24 | 2019-11-29 | 浙江工业大学 | 6-(2-二丙氨基乙酰氨基)喹唑啉类化合物及制备和应用 |
CN108186649B (zh) * | 2018-01-24 | 2020-05-26 | 浙江工业大学 | 丙酰氨基氯代苯并[d]氮杂*基喹唑啉类在制备治疗白血病药物中的应用 |
CN108129461B (zh) * | 2018-01-24 | 2020-08-21 | 浙江工业大学 | 苯甲酰氨基苯并[d]氮杂*基喹唑啉类化合物及制备和应用 |
CN108078994B (zh) * | 2018-01-24 | 2020-01-03 | 浙江工业大学 | 6-(2-吗啉基乙酰氨基)喹唑啉类化合物在制备治疗肺癌药物中的应用 |
CN108164510B (zh) * | 2018-01-24 | 2020-08-21 | 浙江工业大学 | 氯乙酰氨基苯并[d]氮杂*基喹唑啉类化合物及其制备方法和应用 |
CN108125962B (zh) * | 2018-01-24 | 2020-08-21 | 浙江工业大学 | 苯并[d]氮杂*基喹唑啉类化合物在制备治疗肺癌药物中的应用 |
CN108042546B (zh) * | 2018-01-24 | 2020-10-09 | 浙江工业大学 | 吗啉基乙酰氨基苯并[d]氮杂*基喹唑啉类化合物在制备治疗宫颈癌药物中的应用 |
CN109251196B (zh) * | 2018-01-24 | 2020-11-13 | 浙江工业大学 | 氨基苯并[d]氮杂*基喹唑啉类化合物及其制备方法和应用 |
CN108078992B (zh) * | 2018-01-24 | 2020-08-21 | 浙江工业大学 | 特戊酰氨基二甲氧基苯并[d]氮杂*基喹唑啉类化合物在制备治疗白血病药物中的应用 |
CN108125958B (zh) * | 2018-01-24 | 2020-08-21 | 浙江工业大学 | 邻甲苯氨基乙酰氨基氯代苯并氮杂*基喹唑啉类化合物在制备治疗白血病药物中的应用 |
CN108276384B (zh) * | 2018-01-24 | 2019-12-06 | 浙江工业大学 | 乙酰氨基苯并[d]氮杂卓基喹唑啉类化合物及其制备与应用 |
CN108078993B (zh) * | 2018-01-24 | 2020-02-21 | 浙江工业大学 | 6-硝基喹唑啉类化合物在制备治疗肺癌药物中的应用 |
CN108329300B (zh) * | 2018-01-24 | 2020-10-09 | 浙江工业大学 | 硝基苯并[d]氮杂*基喹唑啉类化合物及其制备方法和应用 |
CN108014115B (zh) * | 2018-01-24 | 2020-10-02 | 浙江工业大学 | 特戊酰氨基甲氧苯基苯并[d]氮杂*基喹唑啉类化合物在制备治疗肺癌药物中的应用 |
CN108324718B (zh) * | 2018-01-24 | 2020-10-09 | 浙江工业大学 | 环己基甲氧基甲酰氨基氯代苯并氮杂*基喹唑啉类化合物在治疗白血病药物中的应用 |
CN108245519B (zh) * | 2018-01-24 | 2020-02-21 | 浙江工业大学 | 丁酰氨基喹唑啉类化合物在制备治疗白血病药物中的应用 |
CN108324719B (zh) * | 2018-01-24 | 2020-08-21 | 浙江工业大学 | 邻甲苯氨基乙酰氨基甲氧苯基苯并氮杂*基喹唑啉类化合物在制备治疗宫颈癌药物中的应用 |
CN108245520B (zh) * | 2018-01-24 | 2019-12-24 | 浙江工业大学 | 乙酰氨基喹唑啉类化合物在制备治疗肺癌药物中的应用 |
CN108017621B (zh) * | 2018-01-24 | 2020-08-21 | 浙江工业大学 | 吗啉基乙酰氨基二甲氧基苯并[d]氮杂*基喹唑啉类化合物及制备和应用 |
CN108309984B (zh) * | 2018-01-24 | 2020-02-21 | 浙江工业大学 | 丙酰氨基喹唑啉类化合物在制备治疗宫颈癌药物中的应用 |
CN108117542B (zh) * | 2018-01-24 | 2019-12-24 | 浙江工业大学 | 丙酰氨基甲氧苯基苯并[d]氮杂卓基喹唑啉类化合物及制备和应用 |
CN108276385B (zh) * | 2018-01-24 | 2019-12-06 | 浙江工业大学 | 异丁酰氨基喹唑啉类化合物及其制备与应用 |
CN108143736B (zh) * | 2018-01-24 | 2020-08-21 | 浙江工业大学 | 丁酰氨基苯并[d]氮杂*基喹唑啉类在制备治疗肺癌药物中的应用 |
CN108276386B (zh) * | 2018-01-24 | 2020-10-09 | 浙江工业大学 | 环己基甲氧基甲酰氨基喹唑啉类化合物及制备和应用 |
CN108047206B (zh) * | 2018-01-24 | 2019-11-29 | 浙江工业大学 | 特戊酰氨基苯并[d]氮杂*基喹唑啉类化合物及制备和应用 |
CN108078995B (zh) * | 2018-01-24 | 2020-01-03 | 浙江工业大学 | 苯甲酰氨基喹唑啉类化合物在制备治疗肺癌药物中的应用 |
CN108324717B (zh) * | 2018-01-24 | 2020-08-21 | 浙江工业大学 | 特戊酰氨基氯代苯并[d]氮杂*基喹唑啉类化合物在制备治疗宫颈癌药物中的应用 |
CN108245521B (zh) * | 2018-01-24 | 2020-01-03 | 浙江工业大学 | 二丙氨基乙酰氨基苯并氮杂*基喹唑啉类化合物在制备治疗白血病药物中的应用 |
CN108014114B (zh) * | 2018-01-24 | 2020-08-21 | 浙江工业大学 | 氯乙酰氨基喹唑啉类化合物在制备治疗肺癌药物中的应用 |
CN108125959B (zh) * | 2018-01-24 | 2019-12-31 | 浙江工业大学 | 二甲氧基苯氨基乙酰氨基喹唑啉类化合物在制备治疗白血病药物中的应用 |
WO2024086296A1 (en) * | 2022-10-20 | 2024-04-25 | Mekanistic Therapeutics Llc | Compounds useful in modulating egfr and pi3k |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4012513A (en) * | 1971-11-03 | 1977-03-15 | Imperial Chemical Industries Limited | Indole derivatives for providing analgesic and anti-inflammatory effects |
BE790679A (fr) * | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
WO1992020642A1 (en) * | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
GB9314893D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
-
1995
- 1995-01-27 CZ CZ19962413A patent/CZ288955B6/cs not_active IP Right Cessation
- 1995-01-27 RU RU96119255A patent/RU2137762C1/ru active
- 1995-01-27 CN CN95191723A patent/CN1141633A/zh active Pending
- 1995-01-27 WO PCT/IB1995/000061 patent/WO1995023141A1/en active IP Right Grant
- 1995-01-27 MX MX9603593A patent/MX9603593A/es not_active IP Right Cessation
- 1995-01-27 JP JP7522227A patent/JP2890267B2/ja not_active Expired - Lifetime
- 1995-01-27 EP EP95905737A patent/EP0746554A1/en not_active Withdrawn
- 1995-01-27 CA CA002183655A patent/CA2183655C/en not_active Expired - Fee Related
- 1995-01-27 BR BR9506936A patent/BR9506936A/pt not_active Application Discontinuation
- 1995-01-27 KR KR1019960704612A patent/KR100225721B1/ko not_active IP Right Cessation
- 1995-01-27 AU AU29727/95A patent/AU686843B2/en not_active Ceased
- 1995-01-27 US US08/682,565 patent/US5736534A/en not_active Expired - Fee Related
- 1995-01-27 PL PL95315941A patent/PL315941A1/xx unknown
- 1995-01-27 HU HU9602305A patent/HUT76291A/hu unknown
- 1995-02-06 TW TW084100928A patent/TW404946B/zh not_active IP Right Cessation
- 1995-02-16 IL IL11267395A patent/IL112673A0/xx unknown
- 1995-02-17 PE PE1995262160A patent/PE4896A1/es not_active Application Discontinuation
- 1995-02-22 CO CO95006643A patent/CO4340688A1/es unknown
- 1995-02-22 ZA ZA951458A patent/ZA951458B/xx unknown
-
1996
- 1996-08-19 NZ NZ278135A patent/NZ278135A/en unknown
- 1996-08-22 FI FI963283A patent/FI963283A/fi unknown
- 1996-08-22 NO NO963506A patent/NO963506L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2972795A (en) | 1995-09-11 |
KR970701183A (ko) | 1997-03-17 |
AU686843B2 (en) | 1998-02-12 |
MX9603593A (es) | 1997-03-29 |
RU2137762C1 (ru) | 1999-09-20 |
HUT76291A (en) | 1997-07-28 |
BR9506936A (pt) | 1997-09-09 |
JP2890267B2 (ja) | 1999-05-10 |
CO4340688A1 (es) | 1996-07-30 |
CA2183655A1 (en) | 1995-08-31 |
NZ278135A (en) | 1998-03-25 |
CZ241396A3 (en) | 1997-07-16 |
PL315941A1 (en) | 1996-12-09 |
TW404946B (en) | 2000-09-11 |
HU9602305D0 (en) | 1996-10-28 |
IL112673A0 (en) | 1995-05-26 |
JPH09501953A (ja) | 1997-02-25 |
NO963506L (no) | 1996-10-22 |
WO1995023141A1 (en) | 1995-08-31 |
EP0746554A1 (en) | 1996-12-11 |
ZA951458B (en) | 1996-08-22 |
FI963283A0 (fi) | 1996-08-22 |
FI963283A (fi) | 1996-08-22 |
CA2183655C (en) | 2001-03-06 |
CN1141633A (zh) | 1997-01-29 |
US5736534A (en) | 1998-04-07 |
CZ288955B6 (cs) | 2001-10-17 |
PE4896A1 (es) | 1996-03-09 |
KR100225721B1 (ko) | 1999-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO963506D0 (no) | 4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidler | |
NO20012058D0 (no) | 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler | |
NO20020684L (no) | 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler | |
NO20012057D0 (no) | 2-amino-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler | |
DK0740668T3 (da) | Tetracykliske derivater, fremgangsmåde til deres fremstilling og deres anvendelse | |
NO20020687L (no) | 3(5)-ureido-pyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler | |
NO993003L (no) | Sulfonamid-derivater, fremgangsmÕte for deres fremstilling og deres anvendelse som medikamenter | |
DK0676409T3 (da) | Erythromycinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler | |
EE03482B1 (et) | Kinasoliiniderivaadid, nende valmistamismeetod ja kasutamine | |
NO991815D0 (no) | Oksadiazoler, fremgangsmÕter for deres fremstilling og deres anvendelse som medikamenter | |
NO980720D0 (no) | Pyridazin-3-on-derivater, deres anvendelse og mellomprodukter for deres fremstilling | |
EE04721B1 (et) | Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine | |
NO20011503D0 (no) | Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, deres fremstilling og anvendelse som anorektiske legemidler | |
NO20005146L (no) | Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter | |
NO981522D0 (no) | Aminosyrederivater, deres fremstilling og anvendelse som endotelinantagonister | |
NO955326D0 (no) | Isokinolinderivater, fremgangsmåte for deres fremstilling og terapeutiske anvendelse | |
DK0915845T3 (da) | Acryloylsubstituerede distamycinderivater, fremgangsmåde til fremstilling deraf og anvendelse som antitumormidler og antivirale midler | |
NO943794D0 (no) | 4-difenylmethylpiperidinderivater, og fremgangsmåte for deres fremstilling | |
NO985307D0 (no) | Distamycinderivater, fremgangsmÕte for deres fremstilling, og deres anvendelse som antitumor- og antivirale midler | |
NO951418D0 (no) | Peptidderivater, deres fremstilling og anvendelse som terapeutika | |
NO20010219L (no) | Polycykliske tiazolidin-2-ylidenaminer, fremgangsmÕte for deres fremstilling og deres anvendelse som legemiddel | |
DK0782575T3 (da) | Substituerede pyrazol-pyrazol-derivater, fremgangsmåde til deres fremsstilling samt deres anvendelse som midler med herbicid virkning | |
NO20001288L (no) | Substituerte 1,2,3,4,5,6-heksahydro-2,6-metano-3-benzazocin- 10-oler, fremgangsmõte for fremstilling derav og anvendelse som legemiddel | |
DK0727416T3 (da) | Substituerede benzensulfonylurinstoffer og -thiourinstoffer, og fremgangsmåde til deres fremstilling, deres anvendelse som | |
NO960272L (no) | Oksatiolaner, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder de samme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |